Transporting silence: design of carriers for siRNA to angiogenic endothelium.
The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression. To achieve therapeutic success, however, several hurdles must be overcome including rapid clearance, nuclease degradation, and inefficient intracellular localization. In this presentation, we discuss design strategies for development of self-assembling nanoscale carriers for neovasculature targeted delivery of siRNA inhibiting tumor or ocular angiogenesis.
Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands. r.m.schiffelers@pharm.uu.nl
Raymond M
RM
Schiffelers
Archibald J
AJ
Mixson
Aslam M
AM
Ansari
Marcel H A M
MH
Fens
Quingquan
Q
Tang
Qin
Q
Zhou
Jun
J
Xu
Grietje
G
Molema
Patrick Y
PY
Lu
Puthupparampil V
PV
Scaria
Gert
G
Storm
Martin C
MC
Woodle
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D000818:Animals; D002478:Cells, Cultured; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D006801:Humans; D007202:Indicators and Reagents; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence; D009389:Neovascularization, Pathologic / Q000628:therapy*; D009842:Oligopeptides / Q000008:administration & dosage / Q000737:chemistry; D010455:Peptides / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D007202:Indicators and Reagents; D009842:Oligopeptides; D010455:Peptides; D010714:Phosphatidylethanolamines; D034741:RNA, Small Interfering; C094877:dioleoyl phosphatidylethanolamine; D011092:Polyethylene Glycols; C047981:arginyl-glycyl-aspartic acid